FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit
Replication of Multiple Flaviviruses in Vero Cells

J 2020

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

ŠTEFÁNIK, Michal; James J. VALDES; Fortunatus C. EZEBUO; Jan HAVIERNIK; Ikemefuna C. UZOCHUKWU et al.

Základní údaje

Originální název

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

Autoři

ŠTEFÁNIK, Michal; James J. VALDES; Fortunatus C. EZEBUO; Jan HAVIERNIK; Ikemefuna C. UZOCHUKWU; Martina FOJTÍKOVÁ; Jiří SALÁT; Luděk EYER a Daniel RŮŽEK

Vydání

Microorganisms, Basel, MDPI, 2020, 2076-2607

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10606 Microbiology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.128

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/20:00115772

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

FDA; flavivirus; Zika virus; tick-borne encephalitis virus; West Nile virus; antiviral

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 11. 2020 10:49, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.

Citovat

ŠTEFÁNIK, Michal; James J. VALDES; Fortunatus C. EZEBUO; Jan HAVIERNIK; Ikemefuna C. UZOCHUKWU; Martina FOJTÍKOVÁ; Jiří SALÁT; Luděk EYER a Daniel RŮŽEK. FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms. Basel: MDPI, 2020, roč. 8, č. 4, s. 1-17. ISSN 2076-2607. Dostupné z: https://doi.org/10.3390/microorganisms8040599.

@article{1661516,
   author = {Štefánik, Michal and Valdes, James J. and Ezebuo, Fortunatus C. and Haviernik, Jan and Uzochukwu, Ikemefuna C. and Fojtíková, Martina and Salát, Jiří and Eyer, Luděk and Růžek, Daniel},
   article_location = {Basel},
   article_number = {4},
   doi = {https://doi.org/10.3390/microorganisms8040599},
   keywords = {FDA; flavivirus; Zika virus; tick-borne encephalitis virus; West Nile virus; antiviral},
   language = {eng},
   issn = {2076-2607},
   journal = {Microorganisms},
   title = {FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells},
   url = {https://doi.org/10.3390/microorganisms8040599},
   volume = {8},
   year = {2020}
}

TY  - JOUR
ID  - 1661516
AU  - Štefánik, Michal - Valdes, James J. - Ezebuo, Fortunatus C. - Haviernik, Jan - Uzochukwu, Ikemefuna C. - Fojtíková, Martina - Salát, Jiří - Eyer, Luděk - Růžek, Daniel
PY  - 2020
TI  - FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
JF  - Microorganisms
VL  - 8
IS  - 4
SP  - 1-17
EP  - 1-17
PB  - MDPI
SN  - 20762607
KW  - FDA
KW  - flavivirus
KW  - Zika virus
KW  - tick-borne encephalitis virus
KW  - West Nile virus
KW  - antiviral
UR  - https://doi.org/10.3390/microorganisms8040599
L2  - https://doi.org/10.3390/microorganisms8040599
N2  - Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.
ER  -

ŠTEFÁNIK, Michal; James J. VALDES; Fortunatus C. EZEBUO; Jan HAVIERNIK; Ikemefuna C. UZOCHUKWU; Martina FOJTÍKOVÁ; Jiří SALÁT; Luděk EYER a Daniel RŮŽEK. FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. \textit{Microorganisms}. Basel: MDPI, 2020, roč.~8, č.~4, s.~1-17. ISSN~2076-2607. Dostupné z: https://doi.org/10.3390/microorganisms8040599.

Přehled o publikaci